Rituximab before and during pregnancy
A systematic review, and a case series in MS and NMOSD
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received November 29, 2017
- Accepted in final form February 9, 2018
- First Published March 19, 2018.
Author Disclosures
- Gitanjali Das, BS,
- Vincent Damotte, PhD,
- Jeffrey M. Gelfand, MD, MAS,
- Carolyn Bevan, MD,
- Bruce A.C. Cree, MD,
- Lynn Do, PharmD,
- Ari J. Green, MD, MAS,
- Stephen L. Hauser, MD and
- Riley Bove, MD, MMSc
- Gitanjali Das, BS,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Vincent Damotte, PhD,
NONE
NONE
ECTRIMS committee, Travel grant
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
ARSEP Foundation, France
NONE
NONE
NONE
NONE
NONE
NONE
- Jeffrey M. Gelfand, MD, MAS,
Scientific Advisory board for Genentech. Dr. Gelfand's wife has served on a scientific advisory board for Eli Lilly.
NONE
NONE
Dr. Gelfand's wife is Viewpoints editor for JAMA Neurology.
NONE
NONE
NONE
Dr. Gelfand's wife received compensation for consulting for Zosano, Biohaven and Eli Lilly.
NONE
NONE
NONE
Dr. Gelfand has received research support to UCSF from Genentech, Quest Diagnostics and MedDay. His spouse has received research support to UCSF from eNeura and Allergan.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Dr. Gelfand has received compensation for medical-legal consulting.
- Carolyn Bevan, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Bruce A.C. Cree, MD,
NONE
NONE
NONE
Annals of Neurology, editor, service concluded in 2016.
NONE
NONE
NONE
Abbvie, Biogen, EMD Serono, GeNeuro, Novartis, Sanofi Genzyme.
NONE
NONE
NONE
Contracted research support (clinical trials) from Acorda, Celgene, Hoffman La Roche, MedImmune, Novartis and Teva
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Lynn Do, PharmD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Ari J. Green, MD, MAS,
Medimmune End Point adjudication committee, Novartis Pharmaceuticals OCTIMS sterring committee, Inception 5 Biosciences Founder and Steering Committee, Bionure Scientfic Advisory Board
NONE
NONE
JAMA Neurology Associate Editor Neurology Editorial Board December 2010-2015
Remyelination molecules and pathways
NONE
NONE
Inception 5 Sciences
NONE
NONE
NONE
Novartis Pharma OCTIMs, Inception Sciences SRA
NINDS R01 NS088155-01 NIA 2R01AG038791-06A1
NONE
National MS Society Sherak Foundation Hilton Foundation
Inception 5
NONE
NONE
NONE
NONE
Mylan Pharmaceuticals v Teva Pharmaceuticals Expert Witness
- Stephen L. Hauser, MD and
Serves on scientific advisory board for (1) Symbiotix, (2) Annexon, (3) Bionure, and (4) Molecular Stethoscope; serves on Board of Trustees for (5) Neurona.
NONE
(1) F. Hoffmann La Roche; travel reimbursement for anti-CD20 related meetings and presentations.
NONE
NONE
(1) Harrison's Principles of Internal Medicine, McGraw-Hill Education, 2016
NONE
NONE
NONE
(1) F. Hoffmann La Roche; writing support for anti-CD20 related presentations.
NONE
NONE
(1) NIH, RO1NS026799, PI; RO1NS092835, PI;
NONE
(1) National Multiple Sclerosis Society, RG 2899; (2) Conrad N. Hilton Foundation
NONE
NONE
NONE
NONE
NONE
NONE
- Riley Bove, MD, MMSc
(1) Roche-Genentech (2) Sanofi Genzyme (3) Novartis
(1) Gift from Sherak Foundation (2) Gift from Akili
NONE
NONE
(1) Patent pending - selective estrogen receptor modulators and remyelination.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) California Initiative to Advance Precision Medicine - Demonstration Grant.
(1) UCSF Medical staff (10/2015-current)
(1) National MS Society Career Transition Award (2) Hilton Foundation Research Grant
NONE
NONE
NONE
NONE
NONE
NONE
- From the Department of Neurology, Weill Institute for the Neurosciences, University of California, San Francisco.
- Correspondence
Dr. Bove riley.bove{at}ucsf.edu
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.